Option Care Health Announces Third Quarter Results
06 Novembre 2019 - 12:00PM
Option Care Health, Inc. (Nasdaq: BIOS), the nation’s largest
independent provider of home and alternate site infusion services,
today announced financial results for the third quarter ended
September 30, 2019.
Transaction Highlights
- Completed merger between legacy Option Care Enterprises, Inc.
(“Option Care”) and BioScrip, Inc. (“BioScrip”) organizations on
August 6, 2019 to create Option Care Health, Inc. (“Option Care
Health” or the “Company”)
- Established new Executive Leadership Team and broader field and
functional leadership of the Company, retaining key talent across
both legacy organizations
- Achieved significant progress in integrating commercial
organizations and optimizing commercial resource deployment
- Initiated integration efforts across procurement strategies,
field resource optimization and spending reduction initiatives
John C. Rademacher, Chief Executive Officer, commented, “I’m
pleased to report solid third quarter results and the considerable
progress we have made to integrate our two organizations since the
transaction closed in early August. Our newly combined team has
come together under the unified purpose to set the standard for
infusion therapy in the alternate site setting. While we
still have a significant amount of work ahead of us, I feel we are
on plan and building momentum. Through the hard work of our teams
across various functions, we have developed a comprehensive plan to
deliver at least $60 million in net synergies and I’m excited about
all the opportunities at hand for our combined company.”
Third Quarter 2019 Financial Highlights
Please note that all financial data disclosed below, as well as
in the forthcoming 10-Q, is comprised of the results of legacy
Option Care and its affiliates and incorporate BioScrip results
from August 6, 2019 prospectively. Thus, comparisons to historical
periods are relative to legacy Option Care and its affiliates
only.
- Net revenue of $615.9 million, up 24.7% compared to $493.9
million in the third quarter of 2018
- The deduction for bad debt and contractual adjustments embedded
in net revenue (presented consistent with ASC 606) represented 3.9%
of gross revenue, compared to 2.8% in the third quarter of
2018
- Gross profit of $137.8 million, 22.4% of net revenue, up 27.3%
compared to $108.2 million, 21.9% of revenue, in the third quarter
of 2018
- Net loss of $42.8 million, or $0.07 per share, compared to net
income of $1.8 million, or $0.00 per share, in the third quarter of
2018
- Adjusted EBITDA of $34.8 million, up 32.1% compared to $26.3
million in the third quarter of 2018
- Cash used in operations of $5.8 million impacted by integration
and merger-related outflows, as well as higher disbursements to
remediate legacy BioScrip vendor balances
- Cash balances of $52.8 million at the end of the third quarter
and no outstanding borrowings on the Company’s $150 million
revolver
Conference Call
The conference call can be accessed by dialing (866) 360-3136
for U.S. participants, or (602) 563-8603 for international
participants, and referencing conference ID 9661889; or via a live
audio webcast that will be available online at
https://investors.optioncarehealth.com. A replay of the call will
be available via webcast for on-demand listening shortly after the
completion of the call, at the same web link, and will remain
available for approximately 90 days.
About Option Care Health
Option Care Health (NASDAQ: BIOS), is the largest independent
provider of home and alternate site infusion services in the United
States. With over 6,000 teammates, including approximately
2,900 clinicians, we work compassionately to elevate standards of
care for patients with acute and chronic conditions in all 50
states. Through our clinical leadership, expertise and
national scale, Option Care Health is reimagining the infusion care
experience for patients, customers and employees. To learn more,
please visit our website at OptionCareHealth.com.
Investor Contacts
Mike
Shapiro |
Bob East,
Asher Dewhurst, Jordan Kohnstam |
Chief Financial Officer |
Westwicke |
T: (312) 940-2538 |
T: (413) 213-0500 |
mike.shapiro@optioncare.com
|
optioncarehealth@westwicke.com |
|
|
Forward-Looking Statements – Safe Harbor
This press release may contain “forward-looking statements”
within the meaning of the safe harbor provisions of the U.S.
Private Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by words such as: “anticipate,”
“intend,” “plan,” “believe,” “project,” “estimate,” “expect,”
“may,” “should,” “will” and similar references to future periods.
Examples of forward-looking statements include, among others,
statements we may make regarding future revenues, future earnings,
regulatory developments, market developments, new products and
growth strategies, integration activities and the effects of any of
the foregoing on our future results of operations or financial
conditions.
Forward-looking statements are neither historical facts nor
assurances of future performance. Instead, they are based only on
our current beliefs, expectations and assumptions regarding the
future of our business, future plans and strategies, projections,
anticipated events and trends, the economy and other future
conditions. Because forward-looking statements relate to the
future, they are subject to inherent uncertainties, risks and
changes in circumstances that are difficult to predict and many of
which are outside of our control. Our actual results and financial
condition may differ materially from those indicated in the
forward-looking statements. Important factors that could cause our
actual results and financial condition to differ materially from
those indicated in the forward-looking statements include, among
others, the following: (i) changes in laws and regulations
applicable to our business model; (ii) changes in market conditions
and receptivity to our services and offerings; (iii) results of
litigation; and (iv) the loss of one or more key payers. For a
detailed discussion of the risk factors that could affect our
actual results, please refer to the risk factors identified in our
reports as filed with the SEC.
Any forward-looking statement made by us in this press release
is based only on information currently available to us and speaks
only as of the date on which it is made. We undertake no obligation
to publicly update any forward-looking statement, whether written
or oral, that may be made from time to time, whether as a result of
new information, future developments or otherwise.
Note Regarding Use of Non-GAAP Financial
Measures
In addition to reporting financial information in accordance
with generally accepted accounting principles (GAAP), the Company
is also reporting Adjusted EBITDA, which is a non-GAAP financial
measure. Adjusted EBITDA is not a measurement of financial
performance under GAAP and should not be used in isolation or as a
substitute or alternative to net income, operating income or any
other performance measure derived in accordance with GAAP, or as a
substitute or alternative to cash flow from operating activities or
a measure of the Company’s liquidity. In addition, the Company's
definition of Adjusted EBITDA may not be comparable to similarly
titled non-GAAP financial measures reported by other companies.
Adjusted EBITDA, as defined by the Company, represents net income
before net interest expense, income tax expense, depreciation and
amortization, stock-based compensation expense, and restructuring,
acquisition, integration and other expenses. As part of
restructuring, integration and other expenses, the Company may
incur significant charges such as the write down of certain
long−lived assets, temporary redundant expenses, professional fees,
potential retention and severance costs and potential accelerated
payments or termination costs for certain of its contractual
obligations. Management believes that Adjusted EBITDA provides
useful supplemental information regarding the performance of Option
Care Health’s business operations and facilitates comparisons to
the Company’s historical operating results. For a full
reconciliation of Adjusted EBITDA to the most comparable GAAP
financial measure, please see the attachment to this earnings
release.
|
|
OPTION CARE HEALTH, INC. |
|
CONDENSED CONSOLIDATED BALANCE SHEETS |
|
(IN THOUSANDS) |
|
|
|
|
|
|
|
|
|
|
(unaudited) |
|
|
|
|
September
30, |
|
December
31, |
|
|
2019 |
|
2018 |
|
ASSETS |
|
|
|
|
CURRENT
ASSETS: |
|
|
|
|
Cash and cash equivalents |
$ |
52,789 |
|
|
$ |
36,391 |
|
Accounts receivable, net |
|
336,303 |
|
|
|
310,169 |
|
Inventories |
|
109,235 |
|
|
|
83,340 |
|
Prepaid expenses and other current assets |
|
46,919 |
|
|
|
37,525 |
|
Total current assets |
|
545,246 |
|
|
|
467,425 |
|
|
|
|
|
|
NONCURRENT
ASSETS: |
|
|
|
|
Property and equipment, net |
|
131,982 |
|
|
|
93,142 |
|
Intangible assets, net |
|
395,078 |
|
|
|
219,713 |
|
Goodwill |
|
1,419,373 |
|
|
|
632,469 |
|
Other noncurrent assets |
|
90,246 |
|
|
|
15,462 |
|
Total noncurrent assets |
|
2,036,679 |
|
|
|
960,786 |
|
TOTAL
ASSETS |
$ |
2,581,925 |
|
|
$ |
1,428,211 |
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES
AND STOCKHOLDERS' EQUITY |
|
|
|
|
CURRENT
LIABILITIES: |
|
|
|
|
Accounts payable |
$ |
213,149 |
|
|
$ |
187,886 |
|
Other current liabilities |
|
106,519 |
|
|
|
52,111 |
|
Total current liabilities |
|
319,668 |
|
|
|
239,997 |
|
|
|
|
|
|
NONCURRENT
LIABILITIES: |
|
|
|
|
Long-term debt, net of discount, deferred financing costs, and
current portion |
|
1,259,460 |
|
|
|
535,225 |
|
Other noncurrent liabilities |
|
81,115 |
|
|
|
50,164 |
|
Total noncurrent liabilities |
|
1,340,575 |
|
|
|
585,389 |
|
Total liabilities |
|
1,660,243 |
|
|
|
825,386 |
|
|
|
|
|
|
STOCKHOLDERS' EQUITY |
|
921,682 |
|
|
|
602,825 |
|
TOTAL
LIABILITIES AND STOCKHOLDERS' EQUITY |
$ |
2,581,925 |
|
|
$ |
1,428,211 |
|
|
|
|
|
|
OPTION CARE HEALTH, INC. |
|
|
|
|
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF
EARNINGS |
|
|
|
|
(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS) |
|
|
|
|
|
|
|
|
|
|
|
Three Months
Ended |
|
Nine Months
Ended |
|
|
September 30, |
|
September 30, |
|
|
2019 |
|
2018 |
|
2019 |
|
2018 |
|
|
|
|
|
|
|
|
|
NET REVENUE |
|
$ |
615,880 |
|
|
$ |
493,928 |
|
|
$ |
1,589,638 |
|
|
$ |
1,434,061 |
|
COST OF
REVENUE |
|
|
478,107 |
|
|
|
385,683 |
|
|
|
1,252,281 |
|
|
|
1,122,846 |
|
GROSS
PROFIT |
|
|
137,773 |
|
|
|
108,245 |
|
|
|
337,357 |
|
|
|
311,215 |
|
|
|
|
|
|
|
|
|
|
OPERATING
COSTS AND EXPENSES: |
|
|
|
|
|
|
|
|
Selling, general and administrative expenses |
|
|
133,475 |
|
|
|
85,929 |
|
|
|
315,815 |
|
|
|
258,314 |
|
Depreciation and amortization expense |
|
|
16,023 |
|
|
|
9,557 |
|
|
|
36,142 |
|
|
|
28,180 |
|
Total operating expenses |
|
|
149,498 |
|
|
|
95,486 |
|
|
|
351,957 |
|
|
|
286,494 |
|
OPERATING
(LOSS) INCOME |
|
|
(11,725 |
) |
|
|
12,759 |
|
|
|
(14,600 |
) |
|
|
24,721 |
|
|
|
|
|
|
|
|
|
|
OTHER INCOME
(EXPENSE): |
|
|
|
|
|
|
|
|
Interest expense, net |
|
|
(21,509 |
) |
|
|
(11,025 |
) |
|
|
(44,117 |
) |
|
|
(34,313 |
) |
Other, net |
|
|
(5,984 |
) |
|
|
440 |
|
|
|
(4,661 |
) |
|
|
(1,514 |
) |
Total other expense |
|
|
(27,493 |
) |
|
|
(10,585 |
) |
|
|
(48,778 |
) |
|
|
(35,827 |
) |
|
|
|
|
|
|
|
|
|
(LOSS)
INCOME BEFORE INCOME TAXES |
|
|
(39,218 |
) |
|
|
2,174 |
|
|
|
(63,378 |
) |
|
|
(11,106 |
) |
|
|
|
|
|
|
|
|
|
INCOME TAX
EXPENSE (BENEFIT) |
|
|
3,576 |
|
|
|
383 |
|
|
|
(3,269 |
) |
|
|
(1,737 |
) |
NET (LOSS)
INCOME |
|
$ |
(42,794 |
) |
|
$ |
1,791 |
|
|
$ |
(60,109 |
) |
|
$ |
(9,369 |
) |
|
|
|
|
|
|
|
|
|
Net (loss)
income per share, basic and diluted |
|
$ |
(0.07 |
) |
|
$ |
0.00 |
|
|
$ |
(0.10 |
) |
|
$ |
(0.02 |
) |
|
|
|
|
|
|
|
|
|
OPTION CARE HEALTH, INC. |
|
|
|
|
|
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH
FLOWS |
|
|
|
(IN THOUSANDS) |
|
|
|
|
|
|
|
|
|
|
|
|
|
September 30, |
|
|
|
2019 |
|
2018 |
|
CASH FLOWS
FROM OPERATING ACTIVITIES: |
|
|
|
|
|
Net loss |
|
$ |
(60,109 |
) |
|
$ |
(9,369 |
) |
|
Adjustments to reconcile net loss to net cash provided by
operations: |
|
|
|
|
|
Total depreciation and amortization expense |
|
|
38,997 |
|
|
|
30,447 |
|
|
Other non-cash adjustments |
|
|
21,446 |
|
|
|
1,922 |
|
|
Changes in operating assets and liabilities: |
|
|
|
|
|
Accounts receivable, net |
|
|
71,029 |
|
|
|
(32,483 |
) |
|
Inventories |
|
|
(6,212 |
) |
|
|
4,010 |
|
|
Accounts payable |
|
|
(36,157 |
) |
|
|
8,683 |
|
|
Other |
|
|
(12,424 |
) |
|
|
8,988 |
|
|
Net cash provided by operating activities |
|
|
16,570 |
|
|
|
12,198 |
|
|
|
|
|
|
|
|
CASH FLOWS
FROM INVESTING ACTIVITIES: |
|
|
|
|
|
Acquisition of property and equipment |
|
|
(13,150 |
) |
|
|
(20,716 |
) |
|
Other investing cash flows |
|
|
636 |
|
|
|
- |
|
|
Business acquisitions, net of cash acquired |
|
|
(700,170 |
) |
|
|
(9,917 |
) |
|
Net cash used in investing activities |
|
|
(712,684 |
) |
|
|
(30,633 |
) |
|
|
|
|
|
|
|
CASH FLOWS
FROM FINANCING ACTIVITIES: |
|
|
|
|
|
Proceeds from debt |
|
|
981,050 |
|
|
|
1,000 |
|
|
Retirement of debt obligations |
|
|
(226,738 |
) |
|
|
- |
|
|
Deferred financing costs |
|
|
(36,538 |
) |
|
|
- |
|
|
Other financing cash flows |
|
|
(5,262 |
) |
|
|
(4,112 |
) |
|
Net cash provided by (used in) financing activities |
|
|
712,512 |
|
|
|
(3,112 |
) |
|
NET INCREASE
(DECREASE) IN CASH AND CASH EQUIVALENTS |
|
|
16,398 |
|
|
|
(21,547 |
) |
|
Cash and
cash equivalents - beginning of the period |
|
|
36,391 |
|
|
|
53,116 |
|
|
CASH AND
CASH EQUIVALENTS - END OF PERIOD |
|
$ |
52,789 |
|
|
$ |
31,569 |
|
|
|
|
|
|
|
|
OPTION CARE HEALTH, INC. |
|
|
|
|
QUARTERLY RECONCILIATION BETWEEN GAAP AND NON-GAAP
MEASURES |
|
|
|
|
(IN
THOUSANDS) |
(UNAUDITED) |
|
|
|
|
|
|
|
|
|
|
|
Three Months
Ended |
|
Nine Months
Ended |
|
|
September 30, |
|
September 30, |
|
|
2019 |
|
2018 |
|
|
2019 |
|
2018 |
|
|
|
|
|
|
|
|
|
Consolidated net (loss) income |
|
$ |
(42,794 |
) |
|
$ |
1,791 |
|
|
$ |
(60,109 |
) |
|
$ |
(9,369 |
) |
Interest expense, net |
|
|
21,509 |
|
|
|
11,025 |
|
|
|
44,117 |
|
|
|
34,313 |
|
Income tax expense |
|
|
3,576 |
|
|
|
383 |
|
|
|
(3,269 |
) |
|
|
(1,737 |
) |
Depreciation and amortization expense |
|
|
17,407 |
|
|
|
10,304 |
|
|
|
38,997 |
|
|
|
30,447 |
|
Consolidated
EBITDA |
|
|
(302 |
) |
|
|
23,503 |
|
|
|
19,736 |
|
|
|
53,654 |
|
|
|
|
|
|
|
|
|
|
EBITDA
adjustments |
|
|
|
|
|
|
|
|
Accounting principle changes and non-cash charges |
|
|
4,277 |
|
|
|
- |
|
|
|
8,535 |
|
|
|
- |
|
Stock-based incentive compensation |
|
|
2,745 |
|
|
|
564 |
|
|
|
3,898 |
|
|
|
1,671 |
|
Loss on extinguishment of debt |
|
|
5,469 |
|
|
|
- |
|
|
|
5,469 |
|
|
|
72 |
|
Restructuring, acquisition, integration and other |
|
|
22,585 |
|
|
|
2,261 |
|
|
|
40,151 |
|
|
|
8,554 |
|
Consolidated
adjusted EBITDA |
|
$ |
34,774 |
|
|
$ |
26,328 |
|
|
$ |
77,789 |
|
|
$ |
63,951 |
|
|
|
|
|
|
|
|
|
|
Grafico Azioni BioPlus Acquisition (NASDAQ:BIOS)
Storico
Da Dic 2024 a Gen 2025
Grafico Azioni BioPlus Acquisition (NASDAQ:BIOS)
Storico
Da Gen 2024 a Gen 2025